| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/03/2001 | CA2022486C 1,3-dihydro-1-(pyridinylamino)-2h-indol-2-ones, a process for their preparation and their use as medicaments |
| 04/01/2001 | CA2321593A1 .alpha.-sulfonylamino hydroxamic acid inhibitors of matrix metalloproteinases for the treatment of peripheral or central nervous system disorders |
| 04/01/2001 | CA2321324A1 Quinolin-4yl derivatives |
| 03/30/2001 | WO2003042411A2 Use of mutations of mec-1 and its related genes in the identification of compounds for treatment of disease |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021790A1 Conditional immortalisation of cells |
| 03/29/2001 | WO2001021787A1 Polypeptide humanin inhibiting nerve cell death |
| 03/29/2001 | WO2001021786A1 Method of screening disease depressant gene |
| 03/29/2001 | WO2001021660A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021619A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 03/29/2001 | WO2001021614A1 5-aminoalkyl and 5-aminocarbonyl substituted indoles |
| 03/29/2001 | WO2001021605A2 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food |
| 03/29/2001 | WO2001021600A1 Caspase inhibitor |
| 03/29/2001 | WO2001021598A1 Therapeutic quinazoline compounds |
| 03/29/2001 | WO2001021593A1 New benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity |
| 03/29/2001 | WO2001021591A1 Pyrazole derivatives |
| 03/29/2001 | WO2001021590A1 Muscarinic antagonists |
| 03/29/2001 | WO2001021584A1 Tyrosine derivatives |
| 03/29/2001 | WO2001021582A1 Biphenyl derivatives used as nhe-3 inhibitors |
| 03/29/2001 | WO2001021575A1 Anti-inflammatory nitro- and thia- fatty acids |
| 03/29/2001 | WO2001021214A1 Gene therapy for cerebrovascular disorders |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021202A2 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells |
| 03/29/2001 | WO2001021179A1 Quetiapine granules |
| 03/29/2001 | WO2001021178A2 Method of treating cognitive dysfunction syndrome in dogs and chewable tablet for dogs |
| 03/29/2001 | WO2001021172A1 Anti-cancer nitro- and thia-fatty acids |
| 03/29/2001 | WO2001021156A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | WO2001021015A1 Compositions for use as food and in cosmetics characterised by their antilipoperoxidative properties |
| 03/29/2001 | WO2001007067A3 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 03/29/2001 | WO2001002557A8 Neurotrophic factor receptor |
| 03/29/2001 | WO2000075139A3 Benzothiazinone and benzoxazinone compounds |
| 03/29/2001 | WO2000073294A3 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 03/29/2001 | WO2000059875A3 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 03/29/2001 | WO2000056871A3 CELLS COEXPRESSING AN AMYLOID PRECURSOR PROTEIN AND AN α-SECRETASE AND THEIR USES IN TEST METHODS AND DIAGNOSTICS |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | US20010000075 Neurotactin and uses therefor |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19945302A1 Biphenylderivate als NHE-3-Inhibitoren Biphenyl as NHE-3 inhibitors |
| 03/29/2001 | DE19944767A1 N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel N-substituted 4-Aminopteridine, processes for their preparation and their use as medicaments |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2387529A1 Biphenyl derivatives as nhe-3 inhibitors |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385447A1 Pyrazole derivatives |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383462A1 Therapeutic methods and compounds |
| 03/29/2001 | CA2383253A1 Conditional immortalisation of cells |
| 03/29/2001 | CA2383131A1 Formulation |
| 03/29/2001 | CA2369515A1 Pharmaceutical chewing gum formulations |
| 03/29/2001 | CA2348906A1 Gene therapy for cerebrovascular disorders |
| 03/29/2001 | CA2320556A1 N,n-dichlorinated omega amino acids and uses thereof |
| 03/28/2001 | EP1086706A1 Stabilized compositions containing nootropic drugs |
| 03/28/2001 | EP1086702A2 Method for reduction of headache pain |
| 03/28/2001 | EP1086682A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of neurogenic inflammation |
| 03/28/2001 | EP1086249A2 Diagnostic method based on quantification of extramitochondrial dna |
| 03/28/2001 | EP1086219A2 Proteins regulating gene expression |
| 03/28/2001 | EP1086124A1 Novel cyclosporins |
| 03/28/2001 | EP1086108A1 Heterobicyclic and tricyclic nitric oxide synthase inhibitors |
| 03/28/2001 | EP1086106A1 Furopyridine derivatives and their therapeutical use |
| 03/28/2001 | EP1086103A1 Pyrido 2,3-b]indolizine derivatives and aza analogues thereof; crf 1? specific ligands |
| 03/28/2001 | EP1086102A1 Acetylcholine enhancers |
| 03/28/2001 | EP1086101A1 Beta-carboline compounds |
| 03/28/2001 | EP1086096A1 Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
| 03/28/2001 | EP1086095A1 Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors |
| 03/28/2001 | EP1086093A1 Tetrahydroquinoline derivatives as glycine antagonists |
| 03/28/2001 | EP1086086A1 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 03/28/2001 | EP1086085A1 INHIBITORS OF p38 |
| 03/28/2001 | EP1086084A1 Tetraisoquinololine derivatives as modulators of dopamine d3 receptors |
| 03/28/2001 | EP1086082A1 Arylsubstituted olefinic amines and their use as cholinergic receptors agonists |
| 03/28/2001 | EP1086071A1 Hyperforin derivatives, the use thereof and formulations containing them |
| 03/28/2001 | EP1085901A2 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
| 03/28/2001 | EP1085896A1 Conformationally constrained backbone cyclized somatostatin analogs |
| 03/28/2001 | EP1085895A1 Bradykinin antagonists |
| 03/28/2001 | EP1085894A1 Beta 3-adrenergic receptor agonists |
| 03/28/2001 | EP1085889A2 Novel therapeutic agents that modulate endothelin receptors |
| 03/28/2001 | EP1085887A2 Novel angiotensin receptor modulators and their uses |
| 03/28/2001 | EP1085886A1 Protecting neurons from ischemia |
| 03/28/2001 | EP1085875A1 Use of a nk-1 receptor antagonist for treating psychiatric disorders |
| 03/28/2001 | EP1085873A1 Use of a nk-1 receptor antagonist for treating psychiatric disorders |
| 03/28/2001 | EP1085872A1 INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B |
| 03/28/2001 | EP1085870A2 Multivalent agonists, partial agonists and antagonists of the gaba receptors |
| 03/28/2001 | EP1085868A1 H1-histamine receptor antagonists |
| 03/28/2001 | EP1085862A1 Method of treating an autoimmune disorder |
| 03/28/2001 | EP1085848A2 Inhibitors of transcription factor nf-kappa b |
| 03/28/2001 | EP1085847A2 Novel therapeutic agents that modulate estrogen receptors |
| 03/28/2001 | EP0842178B1 Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission |
| 03/28/2001 | EP0775132B1 (azetidin-1-ylalkyl)lactams as tachykinin antagonists |
| 03/28/2001 | EP0759087B1 Compositions and methods for targeting gene delivery vehicles |
| 03/28/2001 | CN1289336A Chemokine receptor antagonists and methods of use therefor |
| 03/28/2001 | CN1289335A Azolo triazizes and pyrimidines |
| 03/28/2001 | CN1289334A Benzothiadiazoles and derivatives |
| 03/28/2001 | CN1289333A Oxazole derivatives as serotonin-1A receptor ogonists |
| 03/28/2001 | CN1289332A 1,4-Diazacycloheptane derivatives for the treatment of neurological disorders |
| 03/28/2001 | CN1289323A Matrix metalloproteinase inhibitors |
| 03/28/2001 | CN1289322A Hydroxamic and carboxylic acid derivatives |